Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Arbutus Biopharma (ABUS) Misses Q2 EPS by 7c
August 5, 2019 7:37 AM EDTArbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.46), $0.07 worse than the analyst estimate of ($0.39).
Appointed William Collier, with decades of leadership experience in antivirals, President & CEOAnnounced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent capsid inhibitor... More